Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ulcerative Colitis Patients In England Get New Treatment Option

NICE Reverses Initial Rejection Of Janssen’s Stelara

Executive Summary

Stelara is a cost-effective use of National Health Service resources, but only where a TNF-alpha inhibitor has failed or cannot be used, and when the product is offered at the price reduction agreed with the health department’s commercial medicines arm, says the latest advice from England’s health technology assessment body, NICE. The move comes after a similar recommendation made earlier this month by NICE’s counterpart in Scotland.

You may also be interested in...

HTA: Scotland Says Yes To Stelara For Ulcerative Colitis

The decision by the Scottish Medicines Consortium contrasts with recent draft guidance from England’s health technology assessment body, NICE, that recommended against the National Health Service using the Janssen product for ulcerative colitis.

Valneva Starts COVID-19 Vaccine Production In Scotland

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

Stakeholders To Have Say On Future Medicines Verification System In UK

The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts